Your session is about to expire
← Back to Search
Other
ALTO-100 PO Tablet for Depression
Phase 2
Waitlist Available
Research Sponsored by Alto Neuroscience
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up measured at day 1, day 14, day 28, day 42, day 56
Awards & highlights
Summary
This trial is studying a new treatment called ALTO-100. It includes a wide range of participants and aims to understand how the treatment affects the body by collecting biological data.
Eligible Conditions
- Depression
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ measured at day 1, day 14, day 28, day 42, day 56
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~measured at day 1, day 14, day 28, day 42, day 56
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Number of Participants With Clinically Significant Laboratory Abnormalities as a Measure of Safety and Tolerability of ALTO-100
Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability of ALTO-100
To understand the relationship between baseline biology and score change in the Clinical Global Impression scale - Severity (CGI-S) with ALTO-100 from Screening to end of treatment
+1 moreTrial Design
1Treatment groups
Experimental Treatment
Group I: ALTO-100Experimental Treatment1 Intervention
ALTO-100 tablet PO ; twice daily dosing 8 weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ALTO-100 PO Tablet
2022
Completed Phase 2
~30
Find a Location
Who is running the clinical trial?
Alto NeuroscienceLead Sponsor
8 Previous Clinical Trials
1,010 Total Patients Enrolled
8 Trials studying Depression
1,010 Patients Enrolled for Depression
Share this study with friends
Copy Link
Messenger